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Impact of red cell distribution width on future risk of
cancer and all-cause mortality among cancer
patients – the Tromsø Study
Red cell distribution width (RDW) has recently been
associated with the risk of cardiovascular disease and all-
cause mortality.1,2 The underlying mechanisms remain
unresolved, but high levels of RDW may be caused by
inflammation or poor nutritional status.3 Inflammation
and malnutrition are known risk factors of cancer, and
chronic inflammation may lead to cancer in several
organs.4,5 
Recent case control studies have shown associations
between RDW and colon cancer and malign biliary
obstruction.6,7 In addition, RDW has been shown to pre-
dict cancer in patients with unintentional weight loss, and
to be associated with poor prognosis in patients with lung
cancer and multiple myeloma.8-10 Since active malignancy
is accompanied by a prolonged inflammatory response,
and inflammatory processes influence RDW,3,5,11 the retro-
spective design of these previous studies makes it impossi-
ble to determine whether high RDW is causally related to
cancer development. As limited knowledge exists regard-
ing the association between high RDW and future cancer
development or disease activity, we thus performed a large
prospective population-based study to assess the impact of
RDW on future risk of incident cancer, cancer stage and
mortality among cancer patients.  
Participants were recruited from the fourth survey of the
Tromsø Study conducted in 1994-95. A detailed descrip-
tion of the study design and population has been pub-
lished elsewhere.12 The regional committee of medical and
health research ethics approved the study, and all 25 383
included subjects gave their written consent to participate.
Baseline information was collected by self-administered
questionnaires, blood samples and a physical
examination.1 Incident cancer diagnosis, grade and site, as
well as mortality among the cancer patients, were record-
ed from the date of enrolment through to the end of fol-
low-up on December 31, 2010. All cancer diagnoses in the
Norwegian population are registered in the Cancer
Registry of Norway, and information about cancer in the
cohort was obtained by linkage to the cancer registry using
a unique 11-digit personal identification number. In a
recent evaluation of data quality, the Cancer Registry of
Norway had a completeness of 98.8%, with 94% of the
cases being histologically verified.13 Information on mortal-
ity was obtained by linkage to the national Cause of Death
Registry at Statistics Norway.
Statistical analyses were carried out with STATA, ver-
sion 13 (Stata corporation, College Station, TX, USA). For
analyses of the association between RDW and cancer, per-
son-time of follow-up was calculated from the date of
enrolment to the date when cancer was first diagnosed, to
the date when the participant died or moved from the
municipality of Tromsø, or to the end of the study period,
whichever came first. Cox proportional hazard regression
models were used to obtain crude, sex-adjusted, and mul-
tivariable adjusted hazard ratios (HR) with 95% confi-
dence intervals (CI) for incident cancer according to RDW
levels. The lowest RDW quartile was used as the reference
category in the Cox models, and age was used as the
timescale. The multivariable model included BMI, smok-
ing, white blood cell count and haemoglobin. 
For analysis of the association between RDW and all-
cause mortality among cancer patients, person-time was
calculated from the date of cancer diagnosis to the date of
death, date of migration or the end of the study period.
The three lower RDW quartiles were merged and used as
the reference category in the mortality analysis. 
In total, 1 191 men and 1 114 women were diagnosed
with cancer during 332 575 person-years of follow-up
(median 15.7 years). The mean RDW levels were 12.8%
for men and 12.9% for women. In our hospital laboratory,
the reference range for RDW is 11.7-14.5%. Previously, we
have published data on baseline characteristics across cat-
egories of RDW.2 Age, white blood cell counts, proportion
of smokers and subjects with anaemia increased with
higher categories of RDW, whereas the haemoglobin con-
centration decreased. The proportion of subjects with
anaemia, defined as haemoglobin levels <12.0 g/dL in
females and <13.0 g/dL in men, was higher in women than
in men in all RDW categories, while the proportion of
smokers showed a more pronounced increase across RDW
quartiles in men than in women. 
The multivariable-adjusted risk of cancer was 30% high-
er in men in the highest compared with the lowest RDW
quartile (HR 1.30, 95% CI 1.07-1.59) (Table 1), and men
with RDW above the 95th percentile (RDW ≥14.3%) had
an 83% higher cancer risk (HR 1.83, 95% CI 1.43-2.22).
Apparently, there was no significant association between
RDW and the risk of cancer in women (HR upper versus
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Table 1. Sex-specific incidence rates (IRs) and hazard ratios (HRs) with 95 % confidence intervals (CIs) for incident cancer according to
quartiles (Q), and above the 95th percentile, of red cell distribution width (RDW).
RDW (%) Person-years Events Crude IR* Crude HR Multiadjusted
(95% CI) (95% CI) HR** (95% CI)
Men 156 591 1191 7.61 (7.19-8.05)
Q1 (11.0-12.3) 40 081 146 3.64 (3.10-4.28) ref ref
Q2 (12.4-12.7) 43 257 236 5.46 (4.80-6.20) 1.03 (0.84-1.27) 1.02 (0.83-1.26)
Q3 (12.8-13.1) 35 731 288 8.06 (7.18-9.05) 1.15 (0.94-1.40) 1.12 (0.91-1.38)
Q4 (13.2-30.5) 37 522 521 13.89 (12.74-15.13) 1.40 (1.15-1.69) 1.30 (1.07-1.59)
>95th perc. (14.3-30.5) 6 037 157 26.00 (22.24-30.40) 1.94 (1.54-2.46) 1.83 (1.43-2.33)
Women 175 984 1114 6.33 (5.97-6.71)
Q1 (10.7-12.3) 46 047 215 4.67 (4.09-5.34) ref ref
Q2 (12.4-12.7) 44 529 269 6.04 (5.36-6.81) 1.02 (0.85-1.23) 1.01 (0.84-1.21)
Q3 (12.8-13.2) 42 797 287 6.71 (5.97-7.53) 0.99 (0.83-1.19) 0.95 (0.80-1.14)
Q4 (13.3-24.5) 42 610 343 8.05 (7.24-8.95) 1.14 (0.96-1.36) 1.09 (0.91-1.31)
>95th perc. (14.6-24.5) 9 155 57 6.22 (4.80-8.07) 1.06 (0.79-1.42) 1.12 (0.82-1.52)
*Incidence rates are per 1000 person-years; **adjusted for body mass index, smoking, white blood cell count and hemoglobin levels at baseline. Age as time-scale. 
lower quartile: 1.09, 95% CI 0.91-1.31) (Table 1).
However, stratification of women according to age (≥55
years) revealed that women of post-menopausal age had a
similar risk of incident cancer as did men in the same age
group. Women older than 55 in the highest RDW quartile
had a 22% higher risk of incident cancer than women in
the three lower quartiles (HR 1.22, 95% CI 1.02-1.45)
(data not shown). 
There was an association between high RDW and
increased risk of regional and distal metastasis at the time
of diagnosis in men and women of post-menopausal age
(Table 2).  In men, a 1% increase in RDW was associated
with a 21% increased risk of regional cancer spread (HR
1.21, 95% CI 1.11-1.33) and a 19% increased risk of distal
metastasis (HR 1.19, 95% CI 1.06-1.33) after multivariable
adjustment (data not shown). The risk estimates were essen-
tially similar in women.
On average cancer patients were followed for up to 3.9
years after the initial cancer diagnosis (range 1 day to 15
years). The association between RDW and death after can-
cer diagnosis is shown in Table 3. During this period, 500
(46%) female and 590 (51%) male patients died. Male can-
cer patients within the highest RDW quartile had a 25%
higher risk of death during follow-up than men in the
three lower quartiles (HR 1.25, 95% CI 1.05-1.49) after
multivariable adjustment. The association between RDW
and mortality disappeared after further adjustment for
advanced cancer stage at diagnosis (HR quartile 4 versus
quartiles 1-3: 1.09, 95% CI 0.91-1.30). There was a similar
trend among women, though the risk estimate was not
statistically significant (HR quartile 4 versus quartiles 1-3:
1.18, 95% CI 0.97-1.43). 
Our findings are in part supported by previous studies
on the association between RDW and cancer.6-9 In a case-
control study, RDW was higher in 225 patients with colon
cancer compared to 494 cancer-free controls,6 and was
reported to be a useful tool to differentiate between benign
and malign causes of biliary obstruction.7 As occult cancer
may affect RDW through low-grade inflammation, we
excluded 131 participants who were diagnosed with can-
cer within one year after the inclusion date, resulting in a
mean time from inclusion to diagnosis of 9 years. Further,
sensitivity analysis was performed by extending the exclu-
sion interval from one to two years from study inclusion
to cancer diagnosis (excluding an additional 127 subjects)
without affecting the risk estimates for cancer by RDW.
Moreover, adding the time from baseline to cancer diagno-
sis as an extra adjustment variable did not alter the results.
Thus, our findings demonstrate a clear temporal sequence
between exposure (RDW) and outcome (incident cancer). 
While there was no association between RDW and can-
cer among women younger than 55, women older than 55
had a similar risk to men. The prevalence of iron deficiency
anaemia is higher in pre-menopausal than post-
menopausal women,14 and RDW is strongly associated
with iron deficiency anaemia.15 Within the highest RDW
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Table 2. Incidence rates (IRs) and hazard ratios (HRs) with 95 % confidence intervals (CIs) for cancer stage by quartiles (Q) of red cell dis-
tribution width (RDW) stratified by gender and age (women only).
RDW (%) Person-years Events Crude IR* Crude HR Multiadjusted HR**
(95% CI) (95% CI) (95% CI)
Men 
Localized 156 591 461 2.9 (2.7-3.2)
Q1-3 (11.4-13.1) 119 069 289 2.4 (2.2-2.7) ref ref    
Q4 (13.2-19.6) 37 522 172 4.6 (3.9-5.3) 1.07 (0.88-1.30) 1.09 (0.89-1.33)
Regional spread 156 591 274 1.7 (1.6-2.0)
Q1-3 (11.5-13.1) 119 069 159 1.3 (1.1-1.6) ref ref
Q4 (13.2-30.5) 37 522 115 3.1 (2.6-3.7) 1.27 (0.99-1.62) 1.15 (0.89-1.49)
Distal metastasis 156 591 235 1.5 (1.3-1.7)
Q1-3 (11.2-13.1) 119 069 118 1.0 (0.8-1.2) ref ref
Q4 (13.2-18.3) 37 522 117 3.1 (2.6-3.7) 1.58 (1.21-2.05) 1.35 (1.03-1.77)
Women <55 years
Localized 130 949 260 2.0 (1.8-2.2)
Q1-3 (11.4-13.1) 102 210 201 2.0 (1.7-2.3) ref ref
Q4 (13.2-19.8) 28 739 59 2.1 (1.6-2.6) 0.96 (0.72-1.28) 1.00 (0.74-1.36)
Regional spread 130 949 146 1.1 (0.9-1.3)
Q1-3 (11.3-13.2) 102 210 112 1.1 (0.9-1.3) ref ref
Q4 (13.3-18.2) 28 739 34 1.2 (0.8-1.7) 1.00 (0.68-1.47) 1.02 (0.68-1.53)
Distal metastasis 130 949 93 0.7 (0.6-0.9)
Q1-3 (11.1-13.2) 102 210 67 0.7 (0.5-0.8) ref ref
Q4 (13.3-17.2) 28 739 26 0.9 (0.6-1.3) 1.22 (0.78-1.92) 1.14 (0.70-1.84)
Women ≥55 years
Localized 45 034 216 4.8 (4.2-5.4)
Q1-3 (11.4-13.2) 31 163 135 4.3 (3.7-5.1) ref ref
Q4 (13.3-17.3) 13 872 81 5.8 (4.7-7.3) 1.28 (0.97-1.69) 1.23 (0.93-1.64)
Regional spread 45 034 137 3.0 (2.6-3.6)
Q1-3 (11.4-13.2) 31 163 97 3.1 (2.6-3.8) ref ref
Q4 (13.3-18.0) 13 872 40 2.9 (2.1-3.9) 0.88 (0.61-1.27) 0.88 (0.60-1.28)
Distal metastasis  45 034 127 2.8 (2.4-3.4)
Q1-3 (11.7-13.2) 31 163 78 2.5 (2.0-3.2) ref ref
Q4 (13.3-15.5) 13 872 49 3.5 (2.7-4.7) 1.34 (0.94-1.92) 1.30 (0.89-1.88)
*Incidence rates are per 1000 person-years; **adjusted for body mass index, smoking, white blood cell count and hemoglobin level at baseline. Age as time-scale.
quartile in our cohort, 22% of women younger than 55
had anaemia, while the corresponding proportion was 7%
in older women. Moreover, stratification of the cohort
according to anaemia status and adjustment for haemoglo-
bin concentration did not influence the risk estimates for
cancer by RDW (data not shown). Our findings indicate that
anaemia, and iron deficiency in particular, is probably not
the underlying link between high RDW and cancer risk.
We suggest that mechanisms other than anaemia and iron
deficiency without anaemia, such as worsened health con-
ditions with subsequent low-grade inflammation, may
link high RDW to cancer risk. Alternatively, endogenous
sex-hormones may protect pre-menopausal women from
the risk of cancer among those with high RDW.
RDW was associated with advanced cancer stage and
worsened prognosis among cancer patients in our study.
Accordingly, elevated RDW was associated with more
advanced cancers and worse prognosis in a study of 146
patients with multiple myeloma,10 and a correlation was
found between elevated RDW, cancer stage and prognosis
among lung cancer patients.9 In the present study, the
apparent association between RDW and mortality in can-
cer patients was substantially weakened after adjustment
for regional and distal metastasis at cancer diagnosis.
These findings suggest that the correlation between high
RDW and cancer-related mortality could be explained by
the association between high RDW and more advanced
cancer stages at diagnosis. 
We found a dose-dependent relation between RDW and
future risk of cancer in men and in women of post-
menopausal age. The apparent association between RDW
and case-fatality disappeared after adjustment for cancer
stage, suggesting that the relation is explained by the abil-
ity of RDW to predict advanced cancers. Further studies
are warranted to confirm our original findings, and to
explore the underlying mechanism or mechanisms.
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Table 3. Sex-specific hazard ratios (HRs) with 95 % confidence intervals of death following a cancer diagnosis (n=2305) according to quar-
tiles (Q) of red cell distribution width (RDW).
RDW (%) Person-years Events Crude HR Model 1* Model 2^
(95% CI) (95% CI) (95% CI)
Men 4 192 590
Q1-3 (11.2-13.1) 2 440 266 ref ref Ref
Q4 (13.2-30.5) 1 752 324 1.41 (1.19-1.67) 1.25 (1.05-1.49) 1.09 (0.91-1.30)
Women 4 721 500
Q1-3 (11.1-13.2) 3 374 318 ref ref Ref
Q4 (13.3-20.7) 1 321 182 1.21 (1.01-1.46) 1.18 (0.97-1.43) 1.06 (0.87-1.30)
*Model 1 is adjusted for body mass index, smoking, white blood cell count and hemoglobin level; ^model 2: model 1 + regional and distal metastasis; age is time-scale in
both models.
